Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) among patients with heart failure within a large integrated health system

BACKGROUND: Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred in guidelines over angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) for patients with heart failure with reduced ejection fraction (HFrE...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Brendan J, Huang, Cheng-Wei, Chung, Joanie, Neyer, Jonathan R, Liang, Brannen, Yu, Albert S, Kwong, Eric K, Park, Joon S, Hung, Peggy, Sim, John J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372972/
https://www.ncbi.nlm.nih.gov/pubmed/36125061
http://dx.doi.org/10.18553/jmcp.2022.28.10.1173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10372972/
https://www.ncbi.nlm.nih.gov/pubmed/36125061
http://dx.doi.org/10.18553/jmcp.2022.28.10.1173

Ejemplares similares